Google AI

Weekend Times


The Times

PR Newswire

Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals

  • Written by: PR Newswire Asia - The Times Au RSS

SYDNEY, Dec. 9, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share top-line final data from its phase I study of Cantrixil (TRX-E-002-1) in patients with persistent or recurrent ovarian cancer (NCT02903771).

Key Points

  • 25 patients with advanced metastatic ovarian cancer received at least one dose of Cantrixil at six sites in the United States and Australia, comprising 11 patients in Part A (dose escalation) and 14 patients in Part B (dose expansion)
  • Trial achieved its primary objective, determining the maximum tolerated dose (MTD) of Cantrixil to be 5 mg/kg
  • Overall, 16 patients were evaluable for efficacy. One patient demonstrated a complete response (CR) and two patients experienced a partial response (PR), according to industry-standard RECIST criteria, making an overall response rate (ORR) of 19%
  • The patient who experienced a complete response remains in remission some three years after her last dose of Cantrixil
  • The drug was generally well-tolerated, with primarily gastrointestinal toxicities observed (abdominal pain, vomiting, and nausea)

Australian lead investigator, Associate Professor Jim Coward, commented, "this was a heavily pre-treated population, comprising patients with very advanced disease. Existing treatment options for such patients are limited, and there remains an urgent need for new therapies. My colleagues and I are excited by the potential for Cantrixil to provide benefit here, and we look forward to seeing the drug move forward in its development."

Kazia expects the full data to be presented at a suitable academic conference and published in a peer-reviewed journal in 1H CY2021. In accordance with common practice, the full data will remain embargoed until they are formally published, in order not to prejudice the appropriate dissemination of the data, and only top-line data are discussed here.

Kazia CEO, Dr James Garner, commented, "we are very pleased to see the Cantrixil phase I study completed. The data unambiguously demonstrates the potential for Cantrixil to provide benefit in this very challenging patient population. With this positive data in hand, our focus now shifts to partnering activity, and we hope to transition Cantrixil to a company which both shares our belief in its potential and is able to apply the necessary resources and expertise to realise that potential over the next chapter of its development."

Background

The phase I study of Cantrixil in ovarian cancer (NCT02903771) commenced recruitment in December 2016. It was designed in two parts. Part A (dose escalation component) was intended to determine the maximum tolerated dose (MTD) of Cantrixil in women with ovarian cancer. Part B (dose expansion cohort) was intended to seek preliminary evidence of clinical efficacy, as well as providing a deeper understanding of pharmacokinetics and safety of Cantrixil. All patients received two cycles of treatment with Cantrixil monotherapy, followed by up to six cycles in combination with other chemotherapy agents.

Kazia announced completion of Part A in October 2018. At that stage, the study declared 5 mg/kg to be the MTD, and this dose was used for all patients in Part B. The main dose-limiting toxicity (DLT) was abdominal pain. 11 patients received at least one dose of Cantrixil in Part A.

Part B recruited an additional 14 patients, all of whom were treated at the MTD, with the goal of seeking exploratory signals of potential clinical efficacy. All 14 patients received at least one dose of Cantrixil in Part B. In total, 17 patients across Part A and Part B received Cantrixil at the MTD of 5 mg/kg.

The study completed recruitment in August 2019, and last patient last visit occurred in March 2020. Preliminary efficacy data was presented in September 2019 at the European Society for Medical Oncology (ESMO) Annual Meeting in Barcelona, Spain, and at the American Association of Cancer Research (AACR) Virtual Meeting in June 2020.

Read more https://www.prnasia.com/story/archive/3217756_AE17756_0

The Weekend Times Magazine

A Modern Approach to Superannuation: SMSF Setup Online

For Australians seeking greater control over their retirement savings, self-managed superannuation funds (SMSFs) remain an attractive option. Today, advances in digital platforms have streamlined the process, making SMSF setup online faster...

Northern New South Wales may be facing a schoolies invasion

Northern New South Wales may be facing a “schoolies invasion” and unit, apartment and townhouse owners need to prepare – or be left with a potentially large clean-up bill. ...

The Future of the Sales Handoff: From AI SDR to Human Closer

Artificial intelligence is altering the sales process at lightning speed. For many firms, AI is their Sales Development Representative. This class of SDRs completes the initial stage of the sales...

Microbes living on air a global phenomenon

UNSW researchers have found their previous discovery of bacteria living on air in Antarctica is likely a process that occurs globally, further supporting the potential existence of microbial life on...

How Much Should a Small Business Actually Budget for a Website in 2026?

Three quotes land in the same inbox. One says $890. One says $4,600. One says $11,000. All three are for a five-page website for the same Sydney plumbing business. All three...

Science Tutoring and Building Strong Foundations for Academic Success

For students tackling complex scientific concepts, science tutoring provides essential support that turns confusion into clarity. Science subjects demand more than memorisation. They require logical thinking, problem-solving skills, and the ability...

The Importance of Quality Paint Protection for Brisbane Drivers

Shielding Your Vehicle with the Right Protection Every car owner appreciates that fresh showroom finish—the gleam of the paintwork, the smoothness of brand new panels. But once you drive out of...

5 Things You Must Do in Australia

If you are setting sights on Australia as your next holiday destination this year, then you are about to embark on a life-changing adventure. The country offers an exciting and...

Weekend getaways from Perth

You Are in Perth, Australia and You Want to Get Away for the Weekend: What Are the Options? Perth is one of the most isolated cities in the world, but that...

hacklink esim new zealandBetimgrandpashabet girişzlibraryz libraryjojobetcialis 20 mg fiyat